VX-702
VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).

Catalog Number | T2513 |
Research Area | Autophagy|||MAPK |
Molecular Formula | C19H12F4N4O2 |
CAS# | 745833-23-2 |
SMILES | c1cc(c(c(c1)F)N(c1nc(c(cc1)C(=O)N)c1c(cc(cc1)F)F)C(=O)N)F |
Size | 10 mg |
Supplier Page | https://www.targetmol.com/compound/VX-702 |
Additional Information | https://www.targetmol.com/datasheet/T2513 |